The Political Economy of AIDS Treatment: Intellectual Property and the Transformation of Generic Supply

Shadlen, Kenneth C.
September 2007
International Studies Quarterly;Sep2007, Vol. 51 Issue 3, p559
Academic Journal
This article examines the relationship between intellectual property (IP) and public health, with a focus on the extension of AIDS treatment in the developing world. While most of the literature on IP and health examines the conditions affecting poor countries’ capacities to acquire essential medicines, I show the distinct—and more complicated—political economy of production and supply. IP regulations alter the structure of generic pharmaceutical sectors in the countries capable of supplying essential medicines, and changes in market structure affect actors’ economic and political interests and capacities. These new constellations of interests and capacities have profound implications for the creation and maintenance of political coalitions in support of on-going drug supply. The result is that the global AIDS treatment campaign becomes marked by mismatches of interests and capacities: those actors capable of taking the economic, legal, and political steps necessary to increase the supply and availability of essential drugs have diminished interest in doing so, and those actors with an interest in expanding treatment may lack the capacities to address the problem of undersupply. By focusing centrally on actors’ interests in and capacities for economic and political action, the article restores political economy to analysis of an issue-area that has been dominated by attention to international law. And by examining the fragility of the coalitions supporting the production and supply of generic drugs, the article points to the limits of transnational activist networks as enduring agents of change.


Related Articles

  • Drug firms raided at dawn.  // TCE: The Chemical Engineer;Feb2008, Issue 800, p5 

    The article reports on the raids by the European Competition Commission on GlaxoSmithKline, Pfizer, AstraZeneca and Sanofi-Aventis as part of an investigation into the pharmaceutical industries' use of patents. They are investigating whether these companies have abused patent rights to delay the...

  • WTO: Failure to Meet Deadline on Doha Commitments Regarding Access to Generic Drugs. Elliott, Richard // Canadian HIV/AIDS Policy & Law Review;Apr2003, Vol. 8 Issue 1, p38 

    Reports on the failure to meet the deadline on commitments made at the World Trade Organization (WTO) Fourth Ministerial Conference in Doha, Qatar, in November 2001, regarding access to generic drugs. Background on the Ministerial Conference; Adoption of the Declaration on the Trade-Related...

  • Under Review.  // Pharmaceutical Executive;May2002, Vol. 22 Issue 5, p142 

    Highlights several issues critical to the pharmaceutical industry that need to be addressed. Need to balance companies' intellectual property rights with patients' right to access lower-priced generics; Pharmacovigilance and fast-track registration; Biotechnology issues.

  • Antibiotic bill doesn't GAIN enough ground. Ambrose, Paul G. // Nature Medicine;Jul2011, Vol. 17 Issue 7, p772 

    With an eye to tackling the growing problem of antimicrobial drug resistance, US lawmakers last month proposed new incentives to jump-start the ailing antibiotic industry. but the legislation as written is not likely to have the intended consequences, as it fails to adequately shield companies...

  • Indian generic drugs booming. Sanders, Sol W. // East-Asia-Intel Reports;8/22/2007, p8 

    The article reports that Thailand is looking to India for more generic pharmaceuticals. Thailand has rejected efforts by the U.S. to uphold international drug company patents, or at least to seek a legal bypass to permit local production in an emergency. Thailand, China and 10 other nations have...

  • Implications of bilateral free trade agreements on access to medicines. Correa, Carlos María // Bulletin of the World Health Organization;May2006, Vol. 84 Issue 5, p399 

    The TRIPS Agreement of the World Trade Organization (WTO) mandated the introduction of protection of intellectual property rights, notably patents, for pharmaceutical products. While the implications for the access to medicines contained in the terms of this Agreement raised significant...

  • WTO approves TRIPS amendment on importing under compulsory licensing. Herget, Greg // HIV/AIDS Policy & Law Review;Apr2006, Vol. 11 Issue 1, p23 

    The article reports on the amendment of the Trade Related Aspects on Intellectual Property Rights (TRIP) Agreement done by the World Trade Organization (WTO) in August 2003. The original TRIP Agreement allowed governments to issue compulsory licenses authorizing a manufacturer to make, use and...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

  • Dynamics of India's Life Sciences Outsourcing Industry. Bhatt, Nailesh A. // Pharmaceutical Technology;Aug2007 Supplement, Vol. 31, p65 

    The tightening of intellectual property rights in India under GATT/TRIPS was a crucial inflection point for pharmaceutical outsourcing in India. With that move, pharmaceutical outsourcing to that country has evolved from limited partnering options based mainly on generic drugs and limited pure...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics